Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram [mg]) over a time period of 5 days.
Other Name: JNJ-63623872
- The patient has an H7N9 Influenza A infection
- The patient has no known severe hepatic impairment
- Any other Influenza A sub-strains other than H7N9
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.